AGENUS
Agenus develops and commercializes immunotherapies and vaccines for cancer and infectious diseases. The company's treatment aims to stimulate the immune system to recognize and fight cancer cells. Its goal is to treat cancers with novel combinations utilizing its unique portfolio of checkpoint antibodies, tumor microenvironment modifiers, vaccines, and adjuvants. In addition to a broad portfolio, the company has an accomplished team of scientists, novel technology platforms, and fully-integrated end-to-end capabilities from discovery to GMP manufacturing. It was established in 1994 and is headquartered in Lexington, Massachusetts.
AGENUS
Industry:
Biotechnology Medical Medical Device Therapeutics
Founded:
1994-01-01
Address:
Lexington, Massachusetts, United States
Country:
United States
Website Url:
http://www.agenusbio.com
Total Employee:
501+
Status:
Active
Contact:
(781)674-4400
Total Funding:
346.14 M USD
Technology used in webpage:
Domain Not Resolving ReCAPTCHA Cloudflare Hosting Cloudflare CDN CloudFront ASP.NET Ajax Google Analytics IP Anonymization Q4Web Hosting
Similar Organizations
Adaptimmune
Adaptimmune develops T cell therapies to treat cancer, human immunodeficiency virus, and infectious diseases.
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
CEL-SCI
CEL-SCI is a biotechnology company developing immunotherapy products for the treatment of cancer and other infectious diseases.
DNAnexus
DNAnexus develops a cloud platform and global network designed for scientific collaboration and accelerated discovery.
Evaxion Biotech
Evaxion Biotech is devoted to the discovery and development of vaccines against cancer and infectious diseases.
Haemonetics
Haemonetics is a provider of blood and plasma supplies and services.
Halozyme Therapeutics
Halozyme Therapeutics develops extracellular matrix targeting products for the insulin, cancer, dermatology and drug delivery markets.
Humacyte
Humacyte develops products for vascular diseases and replacement of anatomical conduits.
Slingshot Biosciences
Slingshot Biosciences develops next-generation synthetic cells for diagnostics and therapeutics.
Sutro Biopharma
Sutro Biopharma develops protein therapeutics by using OCFS protein synthesis technology.
Current Employees Featured
Brian Corvese Director @ Agenus
Director
Garo Armen Chairman & CEO @ Agenus
Chairman & CEO
1994-01-01
Jennifer S. Buell President & Chief Operating Officer @ Agenus
President & Chief Operating Officer
2020-01-01
Marc van Dijk Chief Technology Officer @ Agenus
Chief Technology Officer
Robin Taylor Chief Commercial Officer @ Agenus
Chief Commercial Officer
2023-07-01
Mark Findeis Executive Director, Research Biochemistry @ Agenus
Executive Director, Research Biochemistry
2020-02-01
Founder
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2015-12-27 | PhosImmune | PhosImmune acquired by Agenus | 44.9 M USD |
| 2015-04-08 | Celexion | Celexion acquired by Agenus | 4 M USD |
| 2014-01-13 | 4-Antibody AG | 4-Antibody AG acquired by Agenus | N/A |
Investors List
Ligand Pharmaceuticals
Ligand Pharmaceuticals investment in Post-IPO Debt - Agenus
Incyte
Incyte investment in Post-IPO Equity - Agenus
Iroquois Capital
Iroquois Capital investment in Post-IPO Equity - Agenus
Hudson Capital Group
Hudson Capital Group investment in Post-IPO Equity - Agenus
Downsview Capital
Downsview Capital investment in Post-IPO Equity - Agenus
Key Employee Changes
| Date | New article |
|---|---|
| 2023-07-20 | Agenus Expands Executive Leadership Team |
Official Site Inspections
http://www.agenusbio.com Semrush global rank: 2.41 M Semrush visits lastest month: 7.92 K
- Host name: 23.185.0.4
- IP address: 23.185.0.4
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Agenus"
Agenus - Wikipedia
Agenus Inc. is a Lexington, Massachusetts-based biotechnology company focused on immunotherapy including immuno-oncology, a field that uses the immune system to control or …See details»
Team - Agenus
Dr. Garo Armen serves as Chairman and Chief Executive Officer of Agenus Inc., which he co-founded in 1994. Under his leadership, Agenus has been advancing breakthrough scientific …See details»
Agenus - LinkedIn
Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company’s mission is to expand patient …See details»
Agenus - Crunchbase Company Profile & Funding
Organization. Agenus . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. ... Contact Email jonae.barnes@agenusbio.com; Phone …See details»
Our History - Agenus
Agenus discovers, manufactures and develops immuno-oncology products. The company’s I-O portfolio is comprised of checkpoint antibodies, cell therapies, vaccines, and adjuvants, representing a combination of synergistic agents to …See details»
Agenus Announces Strategic Realignment to Focus on Core …
LEXINGTON, Mass., December 05, 2024--Agenus Inc., a leader in immuno-oncology, today announced further details of its strategic realignment aimed at streamlining operations, …See details»
Press Release Details - investor.agenusbio.com
Jan 22, 2025 Results from two independent neoadjuvant studies in the U.S. and Europe, enrolling more than 80 patients, underscore BOT/BALs potential to enable chemo-free and …See details»
Agenus Prioritizes Resources to Accelerate Registration and ...
Aug 23, 2023 The plan will reduce operating expenses across Agenus' global organization by concentrating its quality, manufacturing, clinical, regulatory, and research & development …See details»
Agenus Inc. - Agenus Announces Five Presentations at ASCO GI ...
Dec 18, 2024 LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced five presentations featuring botensilimab (BOT, an Fc …See details»
Clinical - Agenus
Agenus clinical operations infrastructure includes over 200 personnel and spans a full suite of capabilities, ranging from medical writing, data management, safety management, statistics, regulatory affairs, clinical monitoring, and program …See details»
Press Release Details - investor.agenusbio.com
Jan 29, 2025 Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations …See details»
Agenus Secures $22 Million Mortgage and Announces Strategic
Nov 27, 2024 Agenus has robust end-to-end development capabilities, across commercial and clinical cGMP manufacturing facilities, research and discovery, and a global clinical operations …See details»
Agenus Announces Strategic Realignment to Focus on Core …
Dec 5, 2024 For more information, visit www.agenusbio.com or @agenus_bio. Information that may be important to investors will be routinely posted on our website and social media …See details»
Patients & Care Partners - Agenus
To learn more about our clinical trials, patient advocacy initiatives or to discuss ways to collaborate, please contact us at: +1 781-384-2053 or med.info@agenusbio.com. Agenus Inc. …See details»
Agenus Reports Q4 and Year-End 2024 Results; Strategic …
Mar 11, 2025 Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational …See details»
Federal government announces support for cutting-edge, AI- and …
20 hours ago OmniaBio Inc. is a technology-focused, global cell and gene therapy contract development and manufacturing organization. A subsidiary of the Centre for …See details»
Pipeline - Agenus
AGEN1181 (Fc-enhanced anti-CTLA-4) Novel innate and adaptive immune activator with broad activity across hot and cold cancers. Tumor cells use the cytotoxic T-lymphocyte antigen 4 …See details»
Establishing Canada’s first large-scale bioinnovation centre
2 days ago Today, the Honourable Darren Fisher, Member of Parliament for Dartmouth – Cole Harbour, announced a $5 million, non-repayable contribution to Neptune BioInnovation Inc. to …See details»
Press Release Details - investor.agenusbio.com
Feb 24, 2025 LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research …See details»
Press Release Details - investor.agenusbio.com
Nov 27, 2024 Agenus Inc. (“Agenus” or the “Company”) (Nasdaq: AGEN), an immuno-oncology company focused on innovation has successfully secured a $22 million non-amortizing …See details»